



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/088,826

08/13/2002

Mark J. Pykett

C01005/70008

5264

23628

7590

12/30/2005

WOLF GREENFIELD & SACKS, PC  
FEDERAL RESERVE PLAZA  
600 ATLANTIC AVENUE  
BOSTON, MA 02210-2211

EXAMINER

BELYAVSKIY, MICHAEL A

ART UNIT

PAPER NUMBER

1644

DATE MAILED: 12/30/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/088,826

Applicant(s)

PYKETT ET AL.

Examiner

Michail A. Belyavskyi

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 03 October 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1,2,5,9-16,18-20 and 24-29 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,2,5,9-16,18-20 and 24-29 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

Art Unit: 1644

## RESPONSE TO APPLICANT'S AMENDMENT

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 09/20/05 has been entered.

2. Claims 1, 2, 5, 9-16, 18-20, 24-29 are pending.

3. *Claims 1, 2, 5, 9-16, 18-20, 24-29 reads on a method for in vitro culture of hematopoietic progenitor cells to produce differentiated cells, wherein differentiated cells are neuronal cells and wherein growth factors are bFGF and EGF and wherein solid matrix is tantalum-coated are under consideration in the instant application.*

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

5. Claims 1, 2, 5, 9-16, 18-20, 24-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 99/15629 in view of the known fact disclosed in the Specification on page 11, lines 9-26 and US Patent 6,830,927.

WO' 629 teaches a method for in vitro culture of hematopoietic progenitor cells to produce differentiated cells of non-hematopoietic lineage ( see entire document, Abstract in particular).

Art Unit: 1644

WO'629 teaches that said cells are cultured under condition that promote differentiation, using three dimensional porous matrix having a unitary microstructure having a percent of open space of at least 75% and having a diameter of pores at mid-point on average of less than 150  $\mu\text{m}$  ( see page 5 lines 12 in particular). WO'629 teaches that porous solid matrix is a metal-coated wherein a metal is tantalum ( see page 5, lines 10-25 in particular). ). WO' 629 teaches porous solid matrix having seeded hematopoietic progenitor cells wherein said cells is impregnated with a gelatinous agent that occupies pores of the matrix ( see pages 8-9 in particular). WO' 629 teaches that hematopoietic progenitor cells are obtained from blood product wherein blood product is unfractionated bone marrow ( see pages 5 and 26 in particular). WO' 629 teaches that hematopoietic progenitor cells are  $\text{CD}34^+$  or  $\text{CD}34^-$  or can be isolated from nonnucleated cells or enriched for cells having a common marker ( see examples 1-4 in particular). WO' 629 teaches that hematopoietic progenitor cells are cultured in the presence of various growth factor that promote differentiation such as bFGF ( see pages 6 , 12, 15 and 16 in particular).

WO' 629 does not explicitly teach a method for in vitro culture of hematopoietic progenitor cells to produce differentiated cells of non-hematopoietic lineage, wherein said differentiated cells are neuronal cells and wherein differentiation conditions comprises bFGF and EGF.

US Patent '927 teaches a method for in vitro culturing progenitor cells to produce neuronal cells ( see entire document, Abstract in particular). US Patent '927 teaches that although growth in the presence of only bFGF is sufficient to induce differentiation into neuronal cells, the presence of EGF in the differentiation medium is required for survival of cells ( see columns 3, lines 1-15, column 6, lines 1-30 and column 21 in particular). US Patent '927 teaches a method for in vitro culturing progenitor cells to produce neuronal cells wherein growth differentiation medium comprises bFGF, EGF and NGF ( see column 11, lines 1-10 Examples 10 and 25 in particular).

The Specification on page 11, lines 9-26 disclosed that at the time the invention was made a growth differentiation factors that promote differentiation into neuronal cells, such as bFGF EGF or NGF were well known to those of ordinary skill in the art.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to apply the teaching of US Patent '927 and the known fact disclosed in the specification on page 11, lines 9-26 to those of WO' 629 to obtain a claimed method for in vitro culture of hematopoietic progenitor cells to produce differentiated cells of non-hematopoietic lineage, wherein said differentiated cells are neuronal cells and wherein differentiation conditions comprises bFGF and EGF.

One of ordinary skill in the art at the time the invention was made would have been motivated to do so, because growth differentiation condition wherein said conditions comprising bFGF and EGF were well known in the art and used to produce neuronal cells as taught by the known fact disclosed on page 11 and US Patent '927. Said conditions can be used in the method for in vitro culturing progenitor cells to produce differentiated cells taught by WO'629. The strongest rationale for combining references is a recognition, expressly or impliedly in the prior art or drawn from a convincing line of reasoning based on established scientific principles or legal

Art Unit: 1644

precedent, that some advantage or expected beneficial result would have been produced by their combination. In re Semaker. 217 USPQ 1, 5 - 6 (Fed. Cir. 1983). See MPEP 2144.

From the combined teaching of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention.

Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

6. No claim is allowed.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskiy whose telephone number is 571/ 272-0840. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571/ 272-0841.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michail Belyavskiy, Ph.D.  
Patent Examiner  
Technology Center 1600  
December 27, 2005

